Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14546673 | 0.80 | ADRB2 (0.42) | ADRB2ADRB1KDM4EALDH1A1TDP1 | |
| SCHEMBL17276076 | 0.79 | ACACB (0.47) | GRM5CYP11B1CYP11B2HCRTR1HCRTR2 | |
| SCHEMBL7320740 | 0.76 | ACACB (0.47) | KDM4EALDH1A1GRM5CYP11B1CYP11B2 | |
| SCHEMBL429686 | 0.76 | LOXL2 (0.54) | ADRB2ADRB1KDM4EALDH1A1TDP1 | |
| SCHEMBL4937230 | 0.75 | MAOB (0.45) | GRM5CYP11B1CYP11B2HCRTR1HCRTR2 | |
| SCHEMBL4929558 | 0.75 | ACACB (0.41) | ALDH1A1EGLN2GRM5CYP11B1CYP11B2 | |
| SCHEMBL7920952 | 0.74 | HCRTR1 (0.40) | ALDH1A1GRM5CYP11B1CYP11B2HCRTR1 | |
| SCHEMBL4930416 | 0.74 | GABRG2 (0.49) | GRM5CYP11B1CYP11B2HCRTR1HCRTR2 | |
| SCHEMBL202446 | 0.74 | ALDH1A1 (0.48) | KDM4EALDH1A1ACACB | |
| SCHEMBL13571061 | 0.74 | EPHX2 (0.44) | EGLN2GRM5CYP11B1CYP11B2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | CHEN GUOQING | 2006-02-23 | — | — | US | disclosed |
| US-6995162-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2005-11-24 | — | — | US | disclosed |
| EP-1537084-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | Amgen Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | ADRB2 172/4885ADRB1 104/4885KDM4E 922/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | ADRB2 308/4885ADRB1 199/4885KDM4E 1133/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | ADRB2 203/4885ADRB1 104/4885KDM4E 1013/4885 |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | ADRB2 172/4885ADRB1 104/4885KDM4E 922/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | ADRB2 203/4885ADRB1 104/4885KDM4E 1013/4885 |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | ADRB2 308/4885ADRB1 199/4885KDM4E 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.